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Abstract
The management of patients and families affected by Huntington disease (HD) is complicated by several factors, both practical and ethical. It can be difficult to
determine the onset of clinically manifest HD (mHD). In addition, it can be challenging to decide when to disclose the diagnosis to the affected individual. Firstly,
the features of HD, an incurable, inherited, neurocognitive disorder that often manifests in young adulthood, influence how the person presents and accepts a
diagnosis. Secondly, a positive genetic test for HD may result in a genetic diagnosis, sometimes years before the development of clinical features and the diagnosis of
mHD. Thirdly, observational studies of unaffected gene expansion carriers documented HD manifestations up to 10 years before the typical presentation for
diagnosis. These developments may permit earlier genetic diagnosis and information regarding the patient’s likely status with respect to the development of clinical
disease. Making the genetic diagnosis of HD and providing information regarding disease status, earlier rather than later, respects the person’s right to know and
preserves honesty in the doctor/patient relationship. Conversely, delaying the diagnosis respects the right not to know, avoids potential discrimination, and permits
the person to live a ‘‘normal’’ life for longer, in the context of a disease without cure. This discussion has implications for other inherited and neurocognitive
disorders.
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Introduction
Huntington Disease (HD) is an incurable, inherited, neurocognitive
disorder1,2 with prominent motor manifestations in addition to non-
motor changes in behavior and cognition. Depression, unawareness
and impulsivity are typical. In HD and many other disorders, a
‘‘genetic diagnosis’’ in an unaffected, premanifest person is possible
with genetic testing, years before it is possible to make a diagnosis
of clinically manifest HD (mHD). These factors influence how the
diagnosis of mHD is made and disclosed. There are many elements to
making a clinical diagnosis. These were summarized by the medical
philosopher, Spicker, who wrote, ‘‘In addition to the acquisition of
differential knowledge on the part of a physician, medical diagnosis
depends on the subtleties of the patient-physician encounter, the
prevailing nosological and conceptual systems in which this encounter
occurs, the current status of biomedical research, and the physician’s
reliance on the accuracy, reliability, and validity of the available labo-
ratory analyses.’’3 These concepts are relevant when we deliver infor-
mation and a diagnosis, including to those with a ‘‘genetic diagnosis’’
before clinical diagnosis. The past 30 years of genetic laboratory
technologies resulted in the discovery of the causative genes for roughly
half of 7,000 Mendelian disorders, many of which are movement
disorders.4,5 Using HD as an example, we consider the complexities of
diagnosis and disclosure in clinical practice in the transition from a
genetic diagnosis only, through the disease prodrome, to the diagnosis
of mHD.
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Conventional clinical diagnosis of disease
In practice, the usual process of disease diagnosis is that the individual
describes their symptoms (complaints) to the physician, who elucidates
the history; examines the patient; discusses the findings, likely diagnosis
and treatment, and the need for further investigation. This process may
differ for chronic, incurable, neurological diseases. Those who are unfami-
liar with HD, for example, may not realize that diagnosis of mHD and
disclosure of diagnosis are best approached in a different manner.
Diagnosis of mHD
In the case of HD, there are features that require caution when a
diagnosis is made and disclosed. A diagnosis of mHD is based on
history and examination, in particular the presence of chorea. There
are, however, many additional aspects to take into consideration. These
factors should be contemplated even when the diagnosis is supported by
a family history and/or confirmatory genetic testing for a pathologic
cytosine-adenine-guanine (CAG) expansion in the huntingtin (HTT)
gene and imaging studies.
The unique nature of HD
HD can present in young people with dementia, which is often
associated with unawareness and impulsivity; indeed, HD was recently
included in the Fifth edition of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-5) as a neurocognitive disorder.2,6–8 Patients
may not present with symptoms or be aware of changes taking place,
including functional impairments and their impact on others, particu-
larly family members. Depression and other behavioral manifestations
are common.1,9 As an inherited and incurable illness, many people
observe the devastating effects on their affected family members. The
person’s reaction to a diagnosis may be unpredictable.
Current diagnostic criteria
The current formal diagnosis of mHD is based only on motor
diagnostic criteria that are part of the Unified Huntington Disease Rating
Scale (UHDRS).10 For a diagnosis of mHD, the clinician rates 4 on the
0 to 4 UHDRS Diagnostic Confidence Limits (DCL) scale. This rating,
calculated after motor examination, indicates .99% certainty that the
rater believes that these motor signs are attributable to mHD. This
assessment tool is used in premanifest and other clinical studies, including
drug trials. Overall motor abnormalities are rated as the Total Motor
Score (TMS). However, there is lack of clarity, as there is no precise
threshold on the TMS to define DCL 4, so this rating depends on the
rater’s expertise. There is a need to review and incorporate the evolving
diversity of disease features, taking into account the DSM-5 definition,
and to formulate a wider definition of mHD and its prodrome.2,11,12
Phenotypic variations in HD presentation
HD has a variable phenotype. Thanks to genetic testing and large
observational studies,13 there is now a better understanding of the
possible presentations and natural history of mHD, in addition to
appreciation of the initial symptoms and signs.14–16 Premanifest studies
indicate that disease is not always motor at onset. Chorea may be absent
and is not essential for clinical diagnosis.17 For example, depression and
apathy are common early manifestations.9 On rare occasions, psychosis
may be the initial presentation. In addition to being common presenta-
tions in younger-onset HD, akinetic-rigid and dystonic syndromes may
occur in adults.1 These and other atypical features (e.g., late age of onset)
can result in an initial clinical presentation many years beyond the earliest
disease manifestations, especially in the absence of a family history.18,19
The impact of premanifest studies and earlier diagnosis
It can be postulated that the disease process begins at birth, but
clinical signs, and less reliably symptoms, only develop when accumu-
lating pathology impairs neurological function.20 There is unequivocal
evidence that the process of HD begins and progresses before the
conventional diagnosis of mHD can be made. Subtle, reproducible
imaging and cognitive, behavioral, psychiatric, motor, and functional
manifestations are documented 10 to 15 years before the expected
motor diagnosis. The principal sources of this information are pivotal
longitudinal studies (Predict HD and TRACK HD)9,14,15 comparing
the natural history of premanifest expansion carriers with noncarriers.
The PHAROS study21 of at-risk people with a family history of HD
reached similar conclusions. Because of these and other studies, it is
apparent that some features might define clinical disease onset much
earlier than the current definition of motor onset. These earliest
disease manifestations can often be recognized in clinical practice and
can lead to earlier diagnosis, as well as to discussion of prodromal
manifestations of HD. There are models predicting the likely age of
onset based on CAG repeat expansion length; however, these are not
sufficiently accurate for use in a clinical setting and are only an
approximate guide.22 It may be possible to use other factors to define
onset, and these could be relevant in clinical trials or in initiating
a proven, protective, or curative intervention in the future.23 For
example, diagnosis could be based on imaging, along with other subtle
motor, behavioral, and cognitive changes. It might also be possible to
use a ‘‘biomarker’’ diagnosis of disease onset, if sufficiently accurate
(e.g., mutant HTT measurement).24 With better understanding of the
natural history of HD in the premanifest to earliest mHD phase, it
would be possible to provide information for potentially affected family
members, regarding their risk of disease inheritance and whether they
might have prodromal signs prior to a definite diagnosis of mHD.21
Some argue that HD be considered as a continuum, avoiding concerns
related to fears of a definite point of diagnosis, and with interventions
based on functional decline. In addition to these issues, great caution is
required when considering how and if this information about the premani-
fest, prodromal, and earliest disease course is interpreted and disclosed.
Caveats in diagnosing HD
Special attention should be directed to certain aspects of diagnosis
and disclosure.
1) Certainty that the manifestations, especially the nonmotor and
early manifestations are HD-related cannot be overemphasized.
When a parent has HD, each child has a 50% chance of inheriting
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the expansion. Those who decide on premanifest testing may receive a
genetic diagnosis, sometimes years in advance of onset of mHD. For
example, an unaffected 18-year old may be a carrier but have years of
fully productive life before any symptoms and signs emerge. During
that time, some symptoms and signs could develop that might not be
HD-related and be wrongly attributed to mHD, such as thyrotoxicosis
with anxiety, tremor, and weight loss. Depression is common in the
general population but can also be a prominent manifestation of HD.9,23
While CAG repeat size does not predict a definitive age of onset, it may
provide some guidance. Nonspecific symptoms in a young patient with a
reduced penetrance repeat size, and hence an expected late onset of
clinical HD, would be unlikely to be attributable to the mutation. Other
behavioral changes (e.g., psychosis in an HD family member) may be
difficult to attribute to mHD.25 Treatment with an antipsychotic agent
might potentially mask signs of chorea in such a patient.
2) Unawareness is common in HD and can be an early disease feature.
Some patients present only when a relative recognizes the signs.6–8
Recognition can be especially challenging when there is no family history
or if there is no caregiver involved. A report from a companion is
desirable since their information about disease impact, both social and
functional (e.g., in the work place), may be more reliable than self-
report.26 Heightened awareness is a concern. In our experience, this is
often a feature of those who commit suicide. Not every patient accepts
the diagnosis of HD, especially if they are unaware of the signs of disease.
3) Manifestations may not have functional impacts. Some signs
of mHD go unnoticed because there are no associated symptoms or
functional effects (e.g., abnormal eye movements and mild chorea).27
Early signs could be unrecognized because some occupations require
fewer cognitive resources or do not depend on fine motor skills.
Advantages of making the diagnosis
There is no cure for HD, but making the diagnosis curtails
unnecessary investigations and allows access to care, family support,
and education. Many manifestations, notably depression and irrit-
ability, are treatable or manageable.23,28 Most would agree that mHD
is best managed by disease-specific services, if available, and before
there is irreversible damage to the patient’s relationships. It can be
argued that the neurologist has a ‘‘duty of care,’’ for example, in
Table 1. Reasons for Disclosure vs. Nondisclosure in Giving a Clinical Diagnosis of HD
Reasons for Giving Full Information and an Earlier Diagnosis
N The right to know
N Honesty in the doctor/patient relationship
N Avoidance of paternalism
N Careful but frank discussion of possible place on the disease trajectory, which may (or may not) allay fears that clinical disease will
develop imminently
N Opportunity to plan a more sustainable career path as disease progresses
N Opportunity to put affairs in order for the future
N Early engagement may avoid the problems of increasing lack of awareness and inability to recognize the need for future care
N Interventions can be made for early HD manifestations identified in the premanifest/prodromal studies (e.g., depression, irritability,
and apathy)
N The potential to reduce irreversible social and personal impact including on the family and caregiver
N Opportunity to involve family members, particularly the genetic family, who arguably have a right to know of their risk
N Adopt a healthy lifestyle with exercise and cognitive training, limited alcohol, and no smoking
N Opportunity for research, including participation in trials in early HD before irreversible pathology accumulates
N Allows access to disease-specific services and care
Reasons for Delaying Information about Earliest Manifestations and Early Diagnosis
N Right not to know
N Fear of discrimination in the workplace and regarding health and other insurance
N Allows a ‘‘normal’’ life for longer
N Avoids a perception of illness ahead of time and a disease ‘‘label’’
N May avoid anxiety in relation to possible disease onset
N May avoid impacts on personal relationships
N Delays fear associated with diagnosis, especially because of knowledge of affected relatives
N Information extrapolated from research studies, especially prediction of onset from trinucleotide length, may not be accurate for an
individual
N Symptoms and signs may not be HD-related
Abbreviation: HD, Huntington Disease.
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situations in which there is some urgency to diagnose mHD. Some
quite advanced, cognitively impaired, and unaware patients live in
dangerous and disadvantaged circumstances that require immediate
intervention. While it may be impossible to prevent all behavioral
symptoms and risky activities (e.g., unsafe driving and financial misman-
agement), a diagnosis and explanation of the manifestations improves
understanding, especially for caregivers, as well as alerting them to
potential problems that could be avoided. Arguably, the ‘‘genetic’’
family (those family members who may have HD or could inherit the
disease) are entitled to know of their risks in a timely manner.29,30
Ethical challenges and disclosure
The determination of when to disclose the diagnosis of HD to an
individual is a matter of clinical judgement.2,11 Assessment should
include not only the history and HD-specific examination (motor,
cognitive, behavioral, functional and social), but also the person’s
degree of awareness of disease signs, and their preparedness to accept a
diagnosis. This applies especially for the genetically tested, premanifest
person who could be relatively unaffected for a number of years. The
consequences of giving or not giving an early diagnosis, providing
information regarding subtle signs, or an estimate of likely age of
onset, must all be considered with great care and sensitivity, while
simultaneously respecting the person’s autonomy.31 In addition,
whether to discuss clinical manifestations with little or no effect on
activities of daily living, with an at-risk or premanifest person, may
depend on the person’s preferences, if known, and the nature of the
therapeutic relationship. The individual may not seek a clinical
diagnosis but rather reassurance that they are without signs of mHD.
The right to know (autonomy), and alternatively not to know, must
be judged against the ethical principles of ‘‘do no harm’’ and ‘‘duty
of care’’ (beneficence).32,33 For example, discussion of signs observed
during a research-only visit is usually not permitted in most research
Table 2. Hypothetical Cases and Comments Reflecting the Authors’ Experience
Case 1: A middle-aged person carried a mutation of the same length as their father who had late-onset disease. Their occupation
required planning and flexibility. The person complained of poor organizational skills at a time when the UHDRS motor score was less
than 5. Neuropsychological testing revealed impairment, attributed to depression and anxiety. Brain MRI showed caudate atrophy.
A diagnosis made on behavioral and imaging data allowed medical retirement. Definite HD motor signs developed 4 years later,
about 20 years younger than the father’s age of onset.
Comments: Individual age of disease onset cannot be predicted from the size of the trinucleotide repeat expansion. Other factors
likely modify age of onset and variation in families. This person with preserved awareness had an occupation that alerted them to
changes. A predominantly nonmotor onset can occur. An early diagnosis before definite motor onset facilitated medical retirement and
supported and validated their perceptions of impairment.
Case 2: A person aged 35 presented after the death of their mother following disease onset at age 45 years. They carried the same size
trinucleotide expansion. They complained of poor organization, planning and depression impacting on their work. Examination
revealed no motor features. The person stopped work to enjoy life. Neuropsychological testing, brain MRI, and PET scans were normal
at presentation and at 3-year follow-up.
Comment: A later onset would be more likely. Referral to a psychiatrist allowed assessment of depression. Not all behavioral and
psychiatric manifestations are the result of HD, however this may be difficult to determine. Withholding the diagnosis until there is
greater certainty that the manifestations are mHD is difficult when the person seeks a diagnosis.
Case 3: A premanifest research participant lives alone and presented alone. They report a high level of functioning, including a job that
requires fine motor skills, but lacked awareness of their obvious chorea. For confidentiality reasons, no workplace report is possible.
No diagnosis was given, but follow-up was arranged. This person continued to work but did not return to follow-up visits.
Comment: The dilemma is whether to inform a person of the diagnosis when unaware and reporting no difficulty, especially without
informant input. Impairment of fine movement may be harmless in some occupations but could have consequences in others that
require fine motor skills. Decisions about when and how to disclose the diagnosis are influenced by the degree of risk to the person and
others, if this is known. Most research protocols do not allow discussion of clinical manifestations at a research visit.
Case 4: A depressed, at-risk young person whose affected father had onset in his 40s has not undergone genetic testing. They discuss
plans for a high-risk career. They are unaware of early signs but ask if there are any changes. Depression was treated, and plans were
delayed until review with a companion. The probable early signs were discussed, baseline neuropsychological testing arranged, and
ongoing review of depression.
Comment: This situation demonstrates the conflict between ‘‘doing no harm’’ versus ‘‘duty of care.’’ It also demonstrates the need for
honesty as this person is unlikely to progress in their chosen career. Although difficult to convey, timely diagnosis prevents future distress
(e.g., investing in a career path that cannot be fulfilled).
Abbreviations: HD, Huntington Disease; mHD, Manifest HD; MRI, Magnetic Resonance Imaging; PET, Positron Emission Tomography;
UHDRS, Unified Huntington Disease Rating Scale.
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protocols. The neurologist, or other clinician, has a dilemma of ‘‘if and
when’’ to inform the patient, especially if there is no apparent func-
tional impact of delivering the diagnosis, and must weigh the ethical
principles involved in knowing and not telling (nondisclosure) versus
‘‘telling too soon.’’34
Disclosure of the diagnosis based on nonmanifest features warrants
special attention, as these may be common in the general population,
(e.g., depression and irritability) but may cause great disability even in
early mHD and are treatable.35 Many of the consequences of earlier
diagnosis are similar to those discussed in the premanifest, genetic
counselling protocols, and in the reviews of premanifest testing36,37
(e.g., possible discrimination).38 In HD, the main focus of discussion
has been on the implications of genetic testing and disclosing a genetic
diagnosis to an unaffected carrier, rather than the dilemma of diagno-
sis of mHD and disclosure of this, a difference from Alzheimer disease
(AD) and dementia.34,39–43
Once a diagnosis is made and disclosed, discrimination may be
more likely, especially when the individual seeks insurance. In some
countries, legislated protection is afforded (e.g., the Genetic Informa-
tion Nondiscrimination Act [GINA] in the US).44 However Green
et al.44 highlight a ‘‘gap in protection’’ between the GINA legislation
protecting the individual’s genetic information and the Americans with
Disabilities Act (ADA), protecting those with manifest disease that
limits their ability. On review of the legislation, Green’s conclusion was
that those with manifest disease but who are not disabled are without
protection. Insurers invariably withhold cover for these clinically
unaffected years and treat people with varied CAG repeat expansion
sizes as having the same prognosis.
Ethical considerations when discussing early findings or giving a
diagnosis prior to mHD
Many possible pros and cons of disclosure or nondisclosure need
consideration before information is provided regarding the expected
age of onset or the earliest signs and diagnosis (see Table 1).
Hypothetical cases and comments
Four hypothetical cases reflect the authors’ experience over many
years (see Table 2). Recommendations for the HD diagnosis and dis-
closure process are shown in Table 3.
Other neurocognitive diseases
Many of the ethical challenges encountered in HD are discussed in
the considerable literature regarding dementia and especially AD. In
AD, there are expanded definitions incorporating recent research into
the premanifest/prodromal phase, biomarker and imaging changes,
and the diagnosis of mild cognitive impairment.45,46 In HD, much has
been written about the ethical implications of premanifest and even
diagnostic testing; however, the dilemmas surrounding mHD diagnosis
and disclosure have been relatively neglected compared with other
forms of dementia. The difficulties interpreting early imaging and
biomarker findings and diagnosis, including the ethics of disclosure
and nondisclosure and patient autonomy and unawareness, have been
reviewed.47 Research has been undertaken to determine patient and
family opinions about disclosure and nondisclosure, as well as those
of health professionals. In their literature review of 47 studies, Werner
et al.42 conclude that ‘‘the move between truth telling and being honest
Table 3. Considerations Regarding HD Diagnosis and Disclosure
The following should be considered:
An individualized approach to every patient is essential
What does this person know about HD, and what are their expectations for the future?
What are the person’s expectations from the clinic visit?
What support do they have?
A companion’s report is valuable, particularly of impact on social and work place function.
The person may not have symptoms or be aware of obvious signs of mHD.
Awareness of signs and disease impact may be linked to adverse outcome (i.e., suicide).
Some signs have no impact on function and go unnoticed.
Look for another explanation as some manifestations are unrelated to mHD (e.g., depression).
In the context of atypical presentations, is onset likely at the particular trinucleotide repeat length?
If unsure, treat the symptom and arrange early review or appropriate referral and follow-up.
Weigh the advantages of an immediate diagnosis and the need for interventions.
Gradual introduction to a definite diagnosis, if this is safe.
What is the impact on others, particularly the family?
Remember the right of genetic family to know their risk in a timely manner.
Discuss future disclosure about mHD, the disease prodrome, and earlier diagnosis after a premanifest genetic test result.
The reaction to disclosure of mHD, and of identifying previously unrecognized prodromal findings, may be
unpredictable.
Abbreviations: HD, Huntington Disease; mHD, Manifest HD.
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while being sensitive and showing concern to patients’ abilities and
needs and fear of doing harm is a continuous struggle that no guideline
can resolve.’’ They recommend a diagnosis disclosure ‘‘process’’ rather
than a diagnosis disclosure ‘‘encounter.’’ The autosomal dominant
inheritance of HD raises additional issues; however, the dilemmas in
dementia diagnosis and disclosure are sufficiently similar to guide
further research in HD.
Conclusion
Many factors must be considered when making and disclosing a
diagnosis of mHD, but this is especially true when a genetic diagnosis
precedes the clinical diagnosis of mHD. For the neurologist or other
clinicians in positions of trust, ethical issues are raised when clinical signs
of mHD are apparent of which the person is unaware. To our knowledge,
this dilemma is not addressed in the HD literature to date, although it has
been recognized in AD34,39–41,46 and in other neurocognitive diseases.
Since identification of the HD mutation over 20 years ago, know-
ledge of the disease course has greatly improved. Strategies to manage
some of the manifestations are possible, even at earlier stages. Genetic
testing and research studies allow a better understanding of phenotypic
and genotypic variations and the premanifest phase, and this could
inform a revised, comprehensive definition of HD. Determining how
to apply this updated definition to the individual with their particular
symptoms, signs, and perception of HD, in addition to when and if the
diagnosis should be delivered, will be paramount. Making a clinical
diagnosis of mHD can be a complex process despite the availability of
genetic testing. The course of HD is long. Most affected people have
many productive years following a premanifest genetic diagnosis or cli-
nical diagnosis and before functional impacts. The complexities arising
when a clinical diagnosis of mHD follows genetic diagnosis have
implications for other inherited and neurodegenerative diseases.48
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